CG 200745

Drug Profile

CG 200745

Alternative Names: CG 200745 phosphoric acid; CG 200745 PPA; CG200745

Latest Information Update: 28 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CrystalGenomics
  • Class Antineoplastics
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cancer
  • Phase I/II Myelodysplastic syndromes; Pancreatic cancer

Most Recent Events

  • 01 Jun 2016 Phase-I/II clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in South Korea (IV)
  • 08 Apr 2016 CrystalGenomics plans a phase I/II trial for Myelodysplastic syndrome (Second-line therapy or greater) in South Korea (IV) (NCT02737462)
  • 01 Mar 2016 Phase-I/II clinical trials in Pancreatic cancer (Metastatic disease, Combination therapy, Inoperable/Unresectable, Late-stage disease, First-line therapy) in South Korea (IV) (NCT02737228)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top